Lupin has gotten endorsement for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to showcase a conventional likeness Syprine Capsules, 250 mg, of Bausch Health US, LLC.

The item would be fabricated at Lupin's Nagpur (Unit 1) office, India.

Trientine Hydrochloride Capsules USP, 250 mg, are demonstrated in the treatment of patients with Wilson's ailment who are narrow minded of penicillamine.

Trientine Hydrochloride Capsules USP (RLD: Syprine) had a yearly deals of around USD 86 million in the U. S.